(-0.07%) 5 474.75 points
(-0.10%) 38 781 points
(-0.04%) 19 914 points
(0.21%) $80.50
(1.43%) $2.83
(0.23%) $2 334.30
(-0.19%) $29.34
(-0.23%) $968.70
(0.01%) $0.932
(-0.15%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
@ $41.75
Išleistas: 17 birž. 2024 @ 19:43
Grąža: -3.39%
Ankstesnis signalas: birž. 17 - 16:34
Ankstesnis signalas:
Grąža: -2.14 %
Live Chart Being Loaded With Signals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases...
Stats | |
---|---|
Šios dienos apimtis | 976 927 |
Vidutinė apimtis | 1.34M |
Rinkos kapitalizacija | 4.89B |
EPS | $-0.540 ( Q1 | 2024-05-07 ) |
Kita pelno data | ( $-0.320 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-11.76 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $2.48 (6.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-20 | Deschatelets Pascal | Buy | 24 500 | Common Stock |
2024-05-20 | Deschatelets Pascal | Sell | 24 500 | Stock Option (Right to Buy) |
2024-05-08 | Deschatelets Pascal | Buy | 78 907 | Common Stock |
2024-05-08 | Deschatelets Pascal | Sell | 56 335 | Common Stock |
2024-05-08 | Deschatelets Pascal | Sell | 22 472 | Common Stock |
INSIDER POWER |
---|
-11.66 |
Last 100 transactions |
Buy: 926 414 | Sell: 1 130 718 |
Tūris Koreliacija
Apellis Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
DLHC | 0.954 |
MPAA | 0.943 |
APDN | 0.942 |
MBIO | 0.935 |
JACK | 0.933 |
ALGT | 0.933 |
SHLS | 0.932 |
TOI | 0.931 |
APVO | 0.929 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
VCTR | -0.945 |
BNTC | -0.941 |
AEYE | -0.94 |
NKTR | -0.939 |
SMTC | -0.938 |
KALU | -0.935 |
FRLA | -0.931 |
RVMD | -0.929 |
CGBD | -0.928 |
GGAL | -0.928 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Apellis Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Apellis Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $396.59M |
Bruto pelnas: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2023 |
Pajamos: | $396.59M |
Bruto pelnas: | $336.38M (84.82 %) |
EPS: | $-4.45 |
FY | 2022 |
Pajamos: | $75.42M |
Bruto pelnas: | $69.79M (92.53 %) |
EPS: | $-6.15 |
FY | 2021 |
Pajamos: | $66.56M |
Bruto pelnas: | $61.36M (92.19 %) |
EPS: | $-8.84 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.